Lachiewicz M P, Khanna N, Gordon A N, Horowitz I R
Eur J Gynaecol Oncol. 2017;38(3):456-458.
Clear cell carcinoma of cervix (CCCC) is a rare cervical neoplasm that is usually associated with diethylstilbestrol (DES) exposure in utero as a primary risk factor. Advanced stage disease typically has poor outcomes and no evidence-based approach exists to guide clinicians in treating this rare disease.
The authors report a case of locally advanced CCCC in a 37-year-old Caucasian female. She underwent chemoradiation therapy that included 109 courses of paclitaxel chemotherapy until no disease could be detected on imaging studies. She is now disease-free 13 years after discontinuing chemotherapy.
A prolonged course of single agent paclitaxel after completing standard radiation therapy was successful in achieving remission in a patient with this rare disease.
宫颈透明细胞癌(CCCC)是一种罕见的宫颈肿瘤,通常与子宫内接触己烯雌酚(DES)作为主要危险因素相关。晚期疾病通常预后较差,且尚无循证方法指导临床医生治疗这种罕见疾病。
作者报告了一名37岁白种女性局部晚期CCCC的病例。她接受了放化疗,包括109个疗程的紫杉醇化疗,直到影像学检查未发现疾病。在停止化疗13年后,她现在无病生存。
在完成标准放疗后,延长单药紫杉醇疗程成功使一名患有这种罕见疾病的患者获得缓解。